LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows 181.2% year over year
Q1 FY2026 selling, general & admin of $7.38M rose 181.2% year over year. Sequentially, it rose 36.9% from the prior quarter. Over 3 fiscal years it compounded at +110.6% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +0.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.38M+36.9% QoQ
- Last fiscal yearDec 2025
- $13.66M+0.0% YoY
- LTMMar 2026
- $18.21M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +181.2% | -100.0% | -281.2 pp |
| 1 year | +0.0% | -100.0% | -100.0 pp |
| 3-year CAGR | +110.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.66M USD
- Year-over-year change
- +0.0%
- 3-year CAGR
- +110.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.66M | +0.0% |
| FY2024 | 2024-12-31 | 13.66M | +286.8% |
| FY2023 | 2023-12-31 | 3.53M | +141.4% |
| FY2022 | 2022-12-31 | 1.46M | — |
Selling, General & Admin vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 selling, general & admin of $18.21M is the lowest of the 10 companies compared; the peer median is $55.57M.
- Over three fiscal years its annual growth of +110.6% compares with a peer median of +24.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.42B | +118480.6% | -4.1% | — | |
| LTM Sep 2026 | $646.09M | +23.5% | +14.1% | 53.7% | |
| LTM Jun 2026 | $139.03M | +19.2% | +2.4% | 3857.6% | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $84.34M | +86.2% | +17.3% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $37.63M | +164.2% | +95.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $23.07M | +35.6% | +29.0% | — | |
| LTM Mar 2026 | $21.89M | -3.6% | +59.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $55.57M | +35.6% | +24.5% | 171.4% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| Weighted Avg Shares | 3.54M | 3.54M | 3.54M | 25.3M |
| Weighted Avg Shares (Diluted) | 3.54M | 3.54M | 3.54M | 25.3M |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.